Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

19. November 2025 07:00 ET | Quelle: Regeneron Pharmaceuticals, Inc.

Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation

Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free survival in CSCC in the adjuvant setting, reducing the risk of...
13. November 2025 07:00 ET | Quelle: Regeneron Pharmaceuticals, Inc.

Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs

Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a BCMAxCD3 bispecific antibody as a monotherapy in this...
08. November 2025 10:46 ET | Quelle: Regeneron Pharmaceuticals, Inc.

Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet

Proof-of-concept trials confirm robust anti-clotting effects for Regeneron’s two mechanistically-distinct antibodies against factor XI, in patients undergoing total knee replacement Trial results...
07. November 2025 08:00 ET | Quelle: Regeneron Pharmaceuticals, Inc.

Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged 6 years...
03. November 2025 16:05 ET | Quelle: Regeneron Pharmaceuticals, Inc.

Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Jefferies London Healthcare Conference at 3:30...
31. Oktober 2025 07:00 ET | Quelle: Regeneron Pharmaceuticals, Inc.

Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award

Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions First and only therapy to specifically target the...
28. Oktober 2025 06:30 ET | Quelle: Regeneron Pharmaceuticals, Inc.

Regeneron Reports Third Quarter 2025 Financial and Operating Results

Third quarter 2025 revenues increased 1% to $3.75 billion versus third quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 27% to $4.86 billion EYLEA HD® U.S. net sales increased 10%...
17. Oktober 2025 07:30 ET | Quelle: Regeneron Pharmaceuticals, Inc.

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation

TARRYTOWN, N.Y., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for...
15. Oktober 2025 07:00 ET | Quelle: Regeneron Pharmaceuticals, Inc.

Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers

TARRYTOWN, N.Y., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data from its advancing oncology pipeline will be shared in seven...
12. Oktober 2025 10:18 ET | Quelle: Regeneron Pharmaceuticals, Inc.

DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss

Nearly all participants (11 of 12) experienced clinically meaningful hearing improvements, including three who achieved normal hearing; eight with longer follow-up showed stability or continued...

Vorherige Seite

Nächste Seite